Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML)
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess the efficacy and safety of elacytarabine versus
investigator's choice treatment in patients with relapsed or refractory acute myeloid
leukemia (AML).